Dr. Levitan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
17876 Saint Clair Ave
Cleveland, OH 44110Phone+1 216-383-2222Fax+1 216-430-2826
Education & Training
UMass Chan Medical SchoolFellowship, Hematology and Medical Oncology, 1984 - 1986
Boston VA Healthcare System (Brockton-West Roxbury)Fellowship, Hematology and Medical Oncology, 1983 - 1984- Boston VA Healthcare System (Brockton-West Roxbury)Residency, Internal Medicine, 1980 - 1983
Tufts University School of MedicineClass of 1980
Certifications & Licensure
OH State Medical License 1991 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer Start of enrollment: 1998 Jan 01
- Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer Start of enrollment: 1999 Mar 01
- Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 1999 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsQuality and cost outcomes of an integrated supportive care program.Elizabeth Weinstein, Matthew Kemmann, Sara L. Douglas, Barbara J. Daly, Nathan Levitan
Supportive Care in Cancer. 2022-01-01 - 26 citationsPhase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapyAfshin Dowlati, S. Subbiah, Matthew M. Cooney, Kimberly Rutherford, Tarek Mekhail
Lung Cancer. 2007-06-01 - 4 citationsRandomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer.Afshin Dowlati, Robert Chapman, S. Subbiah, Pingfu Fu, A. Ness
Investigational New Drugs. 2005-12-01
Press Mentions
IBM Seeks Niche for Watson for OncologyOctober 15th, 2019
Transform Industry of Real World Evidence Solutions Market Is Estimated to Grow Incredible CAGR Till 2023August 21st, 2019
Industry Voices—Here's How AI Is Impacting Cancer Care Right NowJune 28th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
